A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers

Cancer Chemotherapy and Pharmacology

Volumn 77, Issue 4, 2016, Pages 839-846

  Knight, Beverly ^a   Rassam, Danielle ^a   Liao, Shanmei ^a   Ewesuedo, Reginald ^a  

^a PFIZER INC   (United States)

Author keywords

Bevacizumab; Biosimilar; Immunogenicity; PF 06439535; Pharmacokinetics

Indexed keywords

BEVACIZUMAB; BIOSIMILAR AGENT; PF 06439535; UNCLASSIFIED DRUG;

ADULT; APPENDICITIS; AREA UNDER THE CURVE; ARTICLE; CONCUSSION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL PAIN; MYALGIA; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TOOTH ABSCESS; UPPER RESPIRATORY TRACT INFECTION; CLINICAL TRIAL; MIDDLE AGED; NORMAL HUMAN;

ADULT; BEVACIZUMAB; BIOSIMILAR PHARMACEUTICALS; DOUBLE-BLIND METHOD; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED;

EID: 84961214920     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-016-3001-2     Document Type: Article

References (7)

1. European Medicines Agency (2014) Guideline on similar biological medicinal products. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/10/WC500176768.pdf. Accessed 25 Aug 2015
2. US Food and Drug Administration (2015) Scientific considerations in demonstrating biosimilarity to a reference product. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291128.pdf. Accessed 1 May 2015
3. World Health Organization, Expert Committee on Biological Standardization (2009) Guidelines on evaluation of similar biotherapeutic products (SBPs). http://www.who.int/biologicals/areas/biological-therapeutics/BIOTHERAPEUTICS-FOR-WEB-22APRIL2010.pdf. Accessed 4 Feb 2015
4. ® (bevacizumab) prescribing information. http://www.gene.com/download/pdf/avastin-prescribing.pdf. Accessed 20 May 2015
5. Grunder B, Costigan L, Johnson K, Kneeland T, Cirelli D, Dufield R, Kitchen R, Porter T, Rouse J, Rule K (2014) Characterization and similarity assessment of bevacizumab and a proposed biosimilar. Presented at: American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exhibition, San Diego, CA
6. Rule K, Peraza M, Shiue M, Finch G, Thibault S, Rosenberg JA, Leach MW (2015) Nonclinical development of PF-06439535, a potential biosimilar to bevacizumab. Presented at: IASLC 16th World Conference on Lung Cancer (WCLC 2015), Denver, CO
7. Socinski MA, Curigliano G, Jacobs I, Gumbiner B, MacDonald J, Thomas D (2015) Clinical considerations for the development of biosimilars in oncology. MAbs 7:286-293